Press Release

PanTera Breaks Ground on its Actinium Production Center (APC)
Milestone marks the start of a new era in global Ac-225 supply for targeted alpha therapy

[Belgium, Mol], October 3, 2025 – PanTera celebrated yesterday the groundbreaking of its Actinium Production Center (APC), a state-of-the-art facility that will become a cornerstone in the global supply of Actinium-225 (Ac-225), a promising isotope for targeted alpha therapy in cancer treatment.

Earlier this year, PanTera obtained all required nuclear and environmental permits, paving the way to launch the construction of this unique production facility. The APC will host PanTera's proprietary production process, which relies on the irradiation of radium-226 (Ra-226) with high-energy gamma beam to generate Actinium-225.

Construction of the APC will be led by the **Wisico consortium**, comprising **Willemen, Cordeel, SPIE, and Imtech**, based on designs developed by **Tractebel** and **Modulo**.

The building is scheduled to become operational in **2028**, with the first commercial supply of Ac-225 expected in **2029**. Once fully ramped up, the APC will be capable of producing **hundreds of curies of Ac-225 annually**, securing reliable access to this vital isotope for pharmaceutical companies and patients worldwide.

"This groundbreaking represents more than just the start of construction—it symbolizes PanTera's commitment to enabling the future of cancer therapy. With the APC, we will unlock large-scale and sustainable production of Ac-225, providing the reliability that the medical community urgently needs," said Sven Van den Berghe, CEO.

The Actinium Production Center will position Belgium at the forefront of nuclear medicine innovation and make a significant contribution to the global fight against cancer.

A Game-Changer in Targeted Alpha Therapy

Actinium-225 is a promising alpha-emitting radioisotope used in Targeted Alpha Therapy (TAT) for cancer treatment. Its ability to deliver high-energy radiation directly to cancer cells while minimizing damage to surrounding healthy tissue makes it a valuable component in developing effective cancer therapies. PanTera's facility aims to secure the large-scale production of Ac-225, improving accessibility to innovative cancer treatments worldwide.

About PanTera

PanTera originated as a joint venture between IBA and SCK CEN, established to secure the large-scale production of actinium-225 (Ac-225), a promising alpha-emitting radioisotope for targeted cancer therapies. With a Series A funding of €95.6 million and all necessary building blocks available, PanTera is ideally positioned to develop cutting-edge production capabilities to enable the accessibility of innovative cancer treatments based on Ac-225.

PanTera's production strategy is built on two complementary approaches: an Early Supply production leveraging Thorium-229 decay, which will provide Ac-225 as early as 2025, and a Commercial Supply production utilizing the Ra-226 photonuclear reaction to enable large-

scale commercial production by 2028. These initiatives ensure a sustainable and scalable supply chain to meet the growing global demand for Ac-225.

For more information, please contact:

Sven Van den Berghe, CEO PanTera

info@pantera-life.com

PanTera NV, Boeretang 201, 2400 Mol, Belgium

Email: info@pantera-life.com

Website: www.pantera-life.com